Observational study to evaluate pharmacokinetics and pharmacodynamics of docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, and capecitabine in elderly patients.

Observational study to evaluate pharmacokinetics and pharmacodynamics of docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, and capecitabine in elderly patients. - SENIOR (Study to Evaluate Neoplasmatic drugs In Older Recipients)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47924

Enrollment

150

Registered

2012-05-03

Start date

2012-08-02

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer malignancies

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Planned to receive docetaxel, paclitaxel, doxorubicin, gemcitabine, vinorelbine, or capecitabine as regular treatment for cancer; 2. Age >= 70 years; 3. Able and willing to give written informed consent prior to participation in the trial; 4. Able and willing to undergo blood sampling for pharmacokinetics.

Exclusion criteria

Exclusion criteria: No exclusion criteria are applicable.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic parameters Serum concentrations of each included agent (absolute values and relative to data retrieved from adult patients	—

Secondary

Measure	Time frame
Pharmacodynamic parameters (serious) adverse events effectiveness (PFS, RR)	—

Countries

Netherlands

Outcome results